SCHEMBL2723367

SCHEMBL2723367

N#Cc1ccc(NC(=O)c2cc(C(=O)O)ccc2NC(=O)c2cccs2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.54
PRSS12 P56730 1/20 0.53
MEN1 O00255 8/20 0.51
KMT2A Q03164 8/20 0.51
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
TDP1 Q9NUW8 2/20 0.51
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.49
LMNA P02545 1/20 0.47
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534739 0.89 TSHR (0.53) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL8888157 0.82 NPC1 (0.75) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL23011785 0.78 KMT2A (0.57) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL11729204 0.77 MEN1 (0.80) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL12700436 0.76 HTT (0.53) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL12700431 0.76 HTT (0.53) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL22982520 0.72 KMT2A (0.50) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL31311072 0.72 AVPR2 (0.58) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL29732825 0.71 KMT2A (0.65) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL28844966 0.71 KMT2A (0.65) L3MBTL1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130261130-A1 NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2013-10-03 US disclosed
US-20130261130-A1 NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2013-10-03 US disclosed
US-20130261130-A1 NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2013-10-03 US disclosed
EP-2635559-A2 NEUROTRYPSIN INHIBITORS Neurotune AG (CH) 2013-09-11 EP disclosed
WO-2012059442-A2 NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2012-05-10 WO disclosed
WO-2012059442-A2 NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261130-A1 NEUROTRYPSIN INHIBITORS MTPN, CHRNA7, CHRNA10 L3MBTL1 3308/4885PRSS12 5/4885MEN1 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.